TerminatedNCT00256997

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations: Dandenong and 43 more locationsSee all locations and recruitment
Study phase: Phase 4

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateJanuary 2006

Recruitment status: Terminated
Enrollment listed in the registry: 167
Sponsor: Janssen-Ortho Inc., Canada
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: Australia, Canada, United Kingdom, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00256997
Official title: Show the full official title
Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting

Terminated

Dandenong, Australia · Frankston, Australia · Mount Claremont, Australia

40 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Janssen-Ortho Inc., Canada.

Does this study involve medication?

Yes. The study involves medication, including Risperidone long-acting injection (LAI) and Oral atypical Antipsychotic.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.